Literature DB >> 18177257

Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review.

Delia Pudney1, Harold Lau, J D Ruether, Vincent Falck.   

Abstract

Anaplastic Thyroid Carcinoma (ATC) is a rare thyroid tumor with a very aggressive clinical course. The following is a report of five patients with inoperable locally advanced disease treated at our institution using multimodality management consisting of chemotherapy and hyperfractionated accelerated radiotherapy. A flow diagram with management recommendations for inoperable ATC is suggested.

Entities:  

Mesh：

Year:  2007        PMID： 18177257     DOI： 10.1089/thy.2007.0026

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


  8 in total

1.  Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.

Authors:  Akira Yoshida; Kiminori Sugino; Iwao Sugitani; Akira Miyauchi
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

2.  Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism.

Authors:  Vibha Sharma; Deborah Fretwell; Zachary Crees; Anna Kerege; Joshua P Klopper
Journal:  Thyroid       Date:  2010-10       Impact factor: 6.568

Review 3.  Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.

Authors:  P Jiménez-Fonseca; J M Gómez Saez; J Santamaria Sandi; J Capdevila; E Navarro Gonzalez; C Zafon Llopis; T Ramón Y Cajal Asensio; G Riesco-Eizaguirre; E Grande; J C Galofré
Journal:  Clin Transl Oncol       Date:  2016-04-05       Impact factor: 3.405

4.  Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy.

Authors:  Marshall Tulloch-Reid; Monica C Skarulis; Steven I Sherman; Nicholas J Sarlis; Libero Santarpia
Journal:  Anticancer Res       Date:  2009-11       Impact factor: 2.480

5.  Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas.

Authors:  Tae-Yon Sung; Sung Ho Choi; Jung Min Lee; Jong Ju Jeong; Sang-Wook Kang; Woong Youn Chung
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

6.  A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.

Authors:  Ying C Henderson; Abdallah S R Mohamed; Anastasios Maniakas; Yunyun Chen; Reid T Powell; Shaohua Peng; Maria Cardenas; Michelle D Williams; Diana Bell; Mark E Zafereo; Rui Jennifer Wang; Steve E Scherer; David A Wheeler; Maria E Cabanillas; Marie-Claude Hofmann; Faye M Johnson; Clifford C Stephan; Vlad Sandulache; Stephen Y Lai
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

7.  Anaplastic thyroid cancer: ultrasonographic findings and the role of ultrasonography-guided fine needle aspiration biopsy.

Authors:  Hee Jung Suh; Hee Jung Moon; Jin Young Kwak; Ji Soo Choi; Eun-Kyung Kim
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

8.  Outcome after intensity modulated radiotherapy for anaplastic thyroid carcinoma.

Authors:  Xiayun He; Duanshu Li; Chaosu Hu; Zhuoying Wang; Hongmei Ying; Yi Wu
Journal:  BMC Cancer       Date:  2014-04-02       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.